MSCRF Clinical Program
Forecasted
The MSCRF Clinical Program by TEDCO funds clinical research using human stem cells to advance new therapies, with all work conducted at Maryland clinical trial sites.
Funder: Maryland Technology Development Corporation (TEDCO)
Due Dates (Anticipated): June 2027 (Application Submission Deadline, projected)
Funding Amounts: Up to $1,000,000 total direct costs for up to 2 years per award; 1:1 non-state funds match required; no indirect costs allowed.
Summary: Supports clinical research using human stem cells to develop new medical therapies, with all funded work conducted at Maryland clinical trial sites.
Key Information: Clinical projects require FDA IND/IDE clearance prior to applying; all MSCRF-funded work must be performed in Maryland.
Description
The MSCRF Clinical Program, administered by TEDCO, aims to accelerate the translation of human stem cell research into clinical applications that address the prevention, diagnosis, treatment, and cure of human diseases and conditions. The program funds clinical trials utilizing all types of human stem cells or enabling technologies, with an emphasis on projects that can significantly impact healthcare and biotechnology within Maryland. Collaboration across academic, public, and private sectors is encouraged, and the program is open to universities, non-profits, for-profits, and other organizations, provided all MSCRF-funded activities occur at clinical trial sites in Maryland.
